Tanaxel (Paclitaxel)

Model: Liquid Injection (in vial)

Booth No: M625

Characteristic

Strength : 30 mg, 100 mg & 300 mg
Dosage form : Liquid Injection
Indication : Ovarian carcinoma, Breast carcinoma, NSCLC, etc.

Ovarian carcinoma
1. First-line therapy in combination with a platinum compound for the treatment of advanced metastatic carcinoma of the ovary.
2. Second-line therapy for the treatment of advanced metastatic carcinoma of the ovary.

Breast carcinoma
1. Adjuvant treatment of node-positive breast cancer administered sequentially to standard combination therapy.
2. Therapy after relapse within 6 months of adjuvant therapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

Non-small cell lung carcinoma (NSCLC)
1. First-line therapy in combination with a platinum compound for the treatment of non-small cell carcinoma of the lung in patients who are not candidates for potentially curative surgery and / or radiation therapy.

Other Products

Products you may be interested in

Highest Rated Products

Back

Menu

Tanaxel (Paclitaxel)

Characteristic

Other Products

Products you may be interested in

Highest Rated Products